Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia

Wei Liu, Yan Shen, Jennifer M. Plane, David E Pleasure, Wenbin Deng

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL. Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL. Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases.

Original languageEnglish (US)
Pages (from-to)227-239
Number of pages13
JournalExperimental Neurology
Volume230
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Periventricular Leukomalacia
Erythropoietin
Microglia
Ischemia
Oligodendroglia
Inflammation
Leukoencephalopathies
carbamylated erythropoietin
Wounds and Injuries
Brain Diseases
Therapeutics
Myelin Sheath
Premature Infants
Disease Progression
Pathology
Poly (ADP-Ribose) Polymerase-1

Keywords

  • Carbamylated erythropoietin
  • Erythropoietin
  • Hypoxia-ischemia
  • Lipopolysaccharide
  • Microglia
  • Oligodendrocyte
  • PARP-1
  • Periventricular leukomalacia
  • White matter injury

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. / Liu, Wei; Shen, Yan; Plane, Jennifer M.; Pleasure, David E; Deng, Wenbin.

In: Experimental Neurology, Vol. 230, No. 2, 08.2011, p. 227-239.

Research output: Contribution to journalArticle

@article{31fb729db1014e819fbbe6e90ea6f491,
title = "Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia",
abstract = "Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL. Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL. Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases.",
keywords = "Carbamylated erythropoietin, Erythropoietin, Hypoxia-ischemia, Lipopolysaccharide, Microglia, Oligodendrocyte, PARP-1, Periventricular leukomalacia, White matter injury",
author = "Wei Liu and Yan Shen and Plane, {Jennifer M.} and Pleasure, {David E} and Wenbin Deng",
year = "2011",
month = "8",
doi = "10.1016/j.expneurol.2011.04.021",
language = "English (US)",
volume = "230",
pages = "227--239",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia

AU - Liu, Wei

AU - Shen, Yan

AU - Plane, Jennifer M.

AU - Pleasure, David E

AU - Deng, Wenbin

PY - 2011/8

Y1 - 2011/8

N2 - Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL. Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL. Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases.

AB - Periventricular leukomalacia (PVL) is the predominant pathology in premature infants, characterized by prominent cerebral white matter injury, and commonly caused by hypoxia-ischemia and inflammation. Activated microglia trigger white matter damage and play a major role in the development of PVL. Erythropoietin (EPO) and its derivative carbamylated erythropoietin (CEPO) have been shown to be neuroprotective in several brain disease models. Here we investigated whether EPO and CEPO could provide protection in mouse models of PVL induced by hypoxia-ischemia or hypoxia-ischemia-inflammation. We administered EPO or CEPO to mice with PVL, and found that both EPO and CEPO treatments decreased microglia activation, oligodendrocyte damage and myelin depletion. We also noted improved performance in neurological function assays. Inhibited disease progression in PVL mice by EPO or CEPO treatment was associated with decreased poly-(ADP-ribose) polymerase-1 (PARP-1) activity. PARP-1 activity was increased dramatically in activated microglia in untreated mice with PVL. Furthermore, we demonstrated that the neuroprotective properties of EPO and CEPO were diminished after PARP-1 gene depletion. The therapeutic doses of EPO and CEPO used in this study did not interfere with normal oligodendrocyte maturation and myelination. Together, our data demonstrate that EPO and CEPO are neuroprotective in cerebral white matter injury via a novel microglial PARP-1 dependent mechanism, and hold promise as a future treatment for PVL and other hypoxic-ischemic/inflammatory white matter diseases.

KW - Carbamylated erythropoietin

KW - Erythropoietin

KW - Hypoxia-ischemia

KW - Lipopolysaccharide

KW - Microglia

KW - Oligodendrocyte

KW - PARP-1

KW - Periventricular leukomalacia

KW - White matter injury

UR - http://www.scopus.com/inward/record.url?scp=79958746580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958746580&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2011.04.021

DO - 10.1016/j.expneurol.2011.04.021

M3 - Article

VL - 230

SP - 227

EP - 239

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -